Esperion Therapeutics (ESPR) Receivables - Net: 2020-2025
Historic Receivables - Net for Esperion Therapeutics (ESPR) over the last 6 years, with Sep 2025 value amounting to $119.0 million.
- Esperion Therapeutics' Receivables - Net rose 75.42% to $119.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.0 million, marking a year-over-year increase of 75.42%. This contributed to the annual value of $80.1 million for FY2024, which is 65.26% up from last year.
- Esperion Therapeutics' Receivables - Net amounted to $119.0 million in Q3 2025, which was up 10.43% from $107.7 million recorded in Q2 2025.
- Esperion Therapeutics' Receivables - Net's 5-year high stood at $119.0 million during Q3 2025, with a 5-year trough of $17.3 million in Q1 2021.
- Its 3-year average for Receivables - Net is $67.2 million, with a median of $60.4 million in 2024.
- As far as peak fluctuations go, Esperion Therapeutics' Receivables - Net skyrocketed by 85.13% in 2021, and later fell by 27.41% in 2022.
- Esperion Therapeutics' Receivables - Net (MRQ) stood at $22.9 million in 2021, then soared by 47.07% to $33.7 million in 2022, then skyrocketed by 43.78% to $48.5 million in 2023, then soared by 65.26% to $80.1 million in 2024, then surged by 48.46% to $119.0 million in 2025.
- Its Receivables - Net stands at $119.0 million for Q3 2025, versus $107.7 million for Q2 2025 and $81.3 million for Q1 2025.